epidoxorubicin

DRUG2 trials

Sponsors

GlaxoSmithKline, Hoffmann-La Roche

Conditions

Breast CancerNeoplasms, Breast

Phase 2

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

CompletedNCT00429299

GlaxoSmithKlineNeoplasms, Breast

Start: 2006-08-31End: 2012-06-30Updated: 2016-03-22

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

CompletedNCT00559845

Hoffmann-La RocheBreast Cancer

Start: 2008-02-29End: 2015-07-31Updated: 2018-04-09

Related Papers

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.

2021-06-1927 citations

Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).

Journal of Clinical Oncology2020-05-203 citations

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

2013-05-0110 citations